Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.

The reorganization is designed to reduce operating expenses and prioritize consumer marketing for its presbyopia treatment Vizz generated $2.6 million in third-quarter sales, with paid prescriptions ...

VisioSurgical Solutions announced its launch and the start of development of a compact surgical robot for retinal surgery with Kaleidoscope Innovation The founding team of VisioSurgical Solutions ...

Key Takeaways Neera Clase, who has served as interim CCO of Tarsus Pharmaceuticals since July, was appointed as the company’s ...

The first patient has been dosed in Nacuity Pharmaceuticals’ global, confirmatory phase 3 clinical trial of NPI-001 tablets for the treatment of retinitis pigmentosa associated with Usher Syndrome.

Glaukos and RevOpsis Therapeutics have entered into an exclusive license agreement to develop and commercialize RO-104, a tri-specific biologic for the treatment for retinal disease The agreement ...

The discovery could advance understanding of glaucoma, age-related macular degeneration, and other ocular diseases, although studies in humans are needed Researchers from the University of British ...

A study recently published in BMJ Open evaluated the first implementation cycle of a comprehensive 3-year cataract outreach program in Sierra Leone The study found that the program has improved ...

Siloton secured £8.4 million from Innovate UK to accelerate development of its handheld GiraffeOCT retinal imaging system Clinical trials with Sunderland Specialist Eye Hospital will evaluate the ...

The acquisition adds Encelto, the first FDA-approved treatment for adults with idiopathic MacTel type 2, to Alcon’s retina portfolio Alcon announced its acquisition of Neurotech Pharmaceuticals for ...

SpyGlass Pharma announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL (BIM-IOL) System in patients with mild-to-moderate open angle glaucoma or ocular ...